Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Improving efficacy of immune checkpoint blockade for cancer can be facilitated by combining these agents with each other and/or with other conventional or targeted therapies. Interferon and innate immune signaling pathways in immune and tumor cells have emerged as intriguing determinants of response and resistance, often in complex and seemingly paradoxical ways.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cell

Title: Cell

Publisher: Elsevier BV

ISSN (Electronic): 1097-4172

ISSN (Print): 0092-8674

Publication date (Electronic): Apr 07 2016

Volume: 165

Issue: 2

Affiliations

[1 ] Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: andyminn@mail.med.upenn.edu.

[2 ] Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Article

Publisher Item ID: S0092-8674(16)30329-4

DOI: 10.1016/j.cell.2016.03.031

PubMed ID: 27058661

SO-VID: 41dcc6aa-ba8d-41f9-a916-04d5e9e08a8b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 122

See all cited by

- Version 1